The diagnosis of BL and other aggressive B cell Lymphomas, with or without Myc breakpoints, represents an important start-point for future clinical trials to establish different therapeutical strategies for these lymphomas. Here, MYC is linked to B-cell non-Hodgkin lymphoma.